What one share of Trinity Biotech holds
We are a biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. Following the acquisition of the biosensor assets of Waveform Technologies Inc. (“Waveform”) in 2024, we have been developing a range of biosensor devices and related services, beginning with a continuous glucose monitoring (“CGM”) product.
Trinity Biotech’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $2.36 |
|---|---|
| Profit | −$2.01 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.32 |
| Cash and investments | $0.27 |
| Debt | $0.01 |
| Book value | −$3.85 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2015 | $18.28 | $3.98 | $1.29 | $1.11 | — | $46.17 |
| 2016 | $17.60 | −$17.78 | $0.74 | $1.06 | — | $23.67 |
| 2017 | $18.44 | −$7.49 | $0.90 | $0.82 | — | $13.56 |
| 2018 | $18.75 | −$4.27 | $1.45 | −$0.06 | — | $9.16 |
| 2019 | $17.75 | −$5.68 | $0.42 | $0.65 | — | $1.13 |
| 2022 | $15.72 | −$10.31 | $0.28 | −$0.51 | — | −$0.29 |
| 2023 | $7.42 | −$3.14 | $0.10 | −$1.61 | — | −$3.12 |
| 2024 | $3.43 | −$1.77 | $0.02 | −$0.26 | — | −$1.96 |
| 2025 | $2.36 | −$2.01 | $0.00 | −$0.32 | — | −$3.85 |
Common questions about Trinity Biotech
How much does one share of Trinity Biotech earn?
Over its latest fiscal year, Trinity Biotech lost $2.01 for each share on $2.36 of sales.
Does Trinity Biotech pay a dividend?
Trinity Biotech didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is Trinity Biotech’s book value per share?
Trinity Biotech’s book value is negative (−$3.85 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of December 31, 2025.
How much cash and debt does each share of Trinity Biotech have?
Each share of Trinity Biotech has $0.27 of cash and investments and $0.01 of debt, as of December 31, 2025.
What is Trinity Biotech’s free cash flow per share?
−$0.32 per share over its latest fiscal year. Free cash flow is the cash left over after spending on buildings and equipment.
Has Trinity Biotech bought back shares?
Trinity Biotech’s share count rose about 239% from 2015 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.